2Seventy Bio Inc (TSVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has a cash flow conversion efficiency ratio of -0.051x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.97 Million) by net assets ($213.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
2Seventy Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TSVT total debt and obligations for a breakdown of total debt and financial obligations.
2Seventy Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2Seventy Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garanti Faktoring AS
IS:GARFA
|
-0.186x |
|
Perma-Pipe International Holdings Inc
NASDAQ:PPIH
|
-0.064x |
|
Valid Soluções S.A
SA:VLID3
|
0.074x |
|
KYE Systems Corp
TW:2365
|
0.012x |
|
Kenmare Resources PLC
IR:KMR
|
0.060x |
|
Cloud Live Technology Group Co Ltd
SHE:002306
|
-0.026x |
|
Hexagon Composites ASA
OL:HEX
|
-0.014x |
|
PAN Group JSC
VN:PAN
|
0.370x |
Annual Cash Flow Conversion Efficiency for 2Seventy Bio Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of 2Seventy Bio Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 2Seventy Bio Inc (TSVT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $210.81 Million | $-85.00 Million | -0.403x | +38.31% |
| 2023-12-31 | $255.30 Million | $-166.86 Million | -0.654x | +14.43% |
| 2022-12-31 | $310.47 Million | $-237.13 Million | -0.764x | -32.75% |
| 2021-12-31 | $359.82 Million | $-207.03 Million | -0.575x | +36.66% |
| 2020-12-31 | $74.63 Million | $-67.79 Million | -0.908x | +80.91% |
| 2019-12-31 | $43.69 Million | $-207.96 Million | -4.760x | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more